Dr David Ribeiro, CEO of ProAxsis, will be attending the 10th anniversary Biotrinity conference, taking place in London on April 25th-27th 2016, and will be presenting a company update at 16.00h on April 26th. Biotrinity is Europe’s leading investment and biopartnering conference, and attracted over 950 delegates from 30 countries in 2015.
Dr Ribeiro said: “ProAxsis is well advanced in its transition to a commercial operation, with its ProteaseTag® Active Neutrophil Elastase Immunoassay now available for researchers, and its companion point-of-care diagnostic nearing the completion of its development. Events such as Biotrinity continue to provide us with an excellent opportunity to interact with the life sciences community.”
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
Related News
ProAxsis will this week be presenting new data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference …
ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes …
ProAxsis will today be presenting new data on its highly novel active neutrophil elastase (NE) point-of-care test, …
